Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Clinical Study of [18F]FT8 PET/CT in Evaluating Amyloidosis

Authors not listed

Tianjin Medical University · 2025

Abstract

\[18F\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\[18F\]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish \[18F\]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of \[18F\]FT8 PET imaging in human subjects.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Anonymous. (2025). Clinical Study of [18F]FT8 PET/CT in Evaluating Amyloidosis. <em>Tianjin Medical University</em>. https://clinicaltrials.gov/study/NCT07232459
Vancouver
Anonymous. Clinical Study of [18F]FT8 PET/CT in Evaluating Amyloidosis. Tianjin Medical University. 2025.
BibTeX
@misc{anon2025Clinic, title = {Clinical Study of [18F]FT8 PET/CT in Evaluating Amyloidosis}, author = {Anonymous}, journal = {Tianjin Medical University}, year = {2025}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings